Upper urinary tract urothelial carcinoma (UTUC) is categorised into low-risk (LR) and high-risk (HR) groups based on patient ...

Dr. Huang concluded this presentation discussing results of a phase II study of tislelizumab as neoadjuvant treatment for cisplatin-ineligible high-risk upper tract urothelial carcinoma with the ...

Long-term data from QUILT-3.032 showed that NAI plus BCG shows sustained responses in BCG-unresponsive bladder cancer with 84 ...

Uterine carcinosarcoma, also referred to as malignant mixed Müllerian tumor, is a rare and highly aggressive neoplasm predominantly affecting postmenopausal women. Combining carcinomatous and ...

Here, we report a patient diagnosed with lung adenocarcinoma harboring EGFR 19Del L747-A755delinsSKD mutation with co-occurring T790M and trans-C797S mutations, who showed a positive response to ...

Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China ...

Cancer Research publishes impactful original studies, reviews, and opinion pieces of high significance to the broad cancer research community. Cancer Research seeks manuscripts that offer conceptual ...

Different stages (I–II and III–IV) effectively predict the survival rates of lung adenocarcinoma (LUAD) patients, and these lncRNAs can reliably forecast these signatures. GSEA revealed that processes ...

aDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory ...